QURE Share Price Performance
US$13.87
8.82 (174.65%)
60.3% undervalued intrinsic discount
US$34.94
Fair Value
Price US$13.87
AnalystConsensusTarget US$34.94
Fair ValueUS$34.94
Share PriceUS$13.87
60.3% undervalued intrinsic discount
QURE Community Narratives
AN
Fair Value US$34.94 60.3% undervalued intrinsic discount
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Recent QURE News & Updates
uniQure N.V. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.92
- Gross Margin
- -850.06%
- Net Profit Margin
- -1,387.98%
- Debt/Equity Ratio
- -12,668.0%
uniQure N.V. Competitors
Snowflake Analysis
About QURE
- Founded
- 1998
- Employees
- 209
- CEO
- WebsiteView website
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Market Insight
It’s been a while since we checked in on commodity markets, which, like other markets, are having quite the interesting year. In particular, gold continues its march upward, while oil remains in a slump. As for the rest, most have been up and down and ended up close to where they were a year ago. By the end, you’ll see why gold stocks still look cheap despite these record prices — and why oil stocks, oddly enough, look expensive even as crude declines.
Continue reading
Dutch Market Performance
- 7 Days: 4.3%
- 3 Months: 5.9%
- 1 Year: 8.5%
- Year to Date: 10.2%
The market is up 4.3% over the last week, with the Information Technology sector leading the way, up 15%. On the other hand, with a decline of 3.8%, the Communication Services sector is lagging behind. The market is up 8.5% over the last 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›